A method for preparing X-ray activated nanoparticles and its application

By preparing four-layered X-ray activatable nanoparticles, the problems of toxic side effects and immunosuppression in traditional radiotherapy were solved, tumor sensitivity and immune attack were enhanced, and highly efficient treatment of colorectal cancer and inhibition of liver metastasis were achieved.

CN118059237BActive Publication Date: 2026-11-17PEKING UNIVERSITY SHENZHEN HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410121428.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-01-26
Publication Date
2026-11-17
Estimated Expiration
2044-01-26

AI Technical Summary

Technical Problem

Traditional radiotherapy has the toxic side effects of high-dose X-rays on normal tissues and the immunosuppressive properties of the tumor microenvironment, which leads to the failure to completely eradicate the tumor and even metastasis and recurrence.

Method used

X-ray activatable nanoparticles with a four-layer structure were prepared, including a core of NaYbF4:2%Er, a shell of NaYbF4, an outer shell of NaLuF4:15%Tb,5%Gd, and an outermost shell of NaLuF4:20%Gd. The surface was modified with amino functional groups and a biomembrane, and loaded with a photosensitive NO precursor and a TGF-β inhibitor. The nanoparticles were activated by X-rays to generate peroxide nitrite, which enhances tumor sensitivity and immune attack.

Benefits of technology

It improves the treatment efficiency of radiotherapy, enhances the sensitivity of tumors to radiotherapy, stimulates the immune system to attack, inhibits liver metastasis of colorectal cancer, and demonstrates intestinal retention ability in rectal cancer, allowing for precise control of drug release.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118059237B_ABST
    Figure CN118059237B_ABST
Patent Text Reader

Abstract

This invention discloses a method for preparing X-ray activatable nanoparticles and their applications, belonging to the field of optical biological imaging technology. The preparation method includes the following steps: First, Er is prepared using a thermal pyrolysis method. 3+ An ion-doped NaYbF4 core was prepared to obtain a core NaYbF4:2%Er. Next, a NaYF4 shell, a NaLuF4:15%Tb,5%Gd outer shell, and a NaLuF4:20%Gd outermost shell were sequentially grown on the surface of the NaYbF4:2%Er core using a thermal injection method to obtain the radiosensitized nanoparticle needle precursor NaYbF:Er@NaYbF4@NaLuF:15%Tb,5%Gd@NaLuF4:20%Gd, i.e., LN. Then, LN was loaded into a hollow structure with an amino-modified silicon shell to form LN@hmSiO-NH22 (LNS). Finally, Russen black salt (RBS) and a transforming growth factor-β (TGF-β) inhibitor (SB525334) were encapsulated into LNS to obtain the radiosensitized nanoparticles LNS-RS. The radiosensitized nanoparticles prepared by the method of the present invention have a four-layer structure and a biological membrane camouflage. The multilayer structure can protect the core while attaching functionalized molecules to the outer shell, and the hollow structure increases the drug loading capacity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of optical biological imaging technology, and in particular relates to a method for preparing X-ray activatable nanoparticles and their applications. Background Technology

[0002] In clinical treatment, radiotherapy (RT) is a primary treatment method that uses high-energy radiation, such as X-rays, to damage the DNA of tumor cells, leading to tumor cell death or inhibiting their growth. However, traditional radiotherapy has some limitations, including the toxic side effects of high-dose X-rays on normal tissues and the immunosuppressive properties of the tumor microenvironment (TME), which may result in incomplete tumor eradication or even metastasis and recurrence.

[0003] To address these challenges, a method is proposed that includes developing an X-ray-controlled drug activation system to improve the sensitivity of radiotherapy and reduce systemic toxicity. X-ray-mediated drug activation technology utilizes ionizing radiation-driven chemical reactions to control the release of chemotherapeutic drugs, potentially enabling precise therapeutic effects—that is, the "real-time" release of drugs at the tumor site without affecting surrounding healthy tissue.

[0004] It should be noted that the above content falls within the inventor's technical knowledge and does not necessarily constitute prior art. Summary of the Invention

[0005] To address the aforementioned problems, the present invention aims to provide a method for preparing X-ray activatable nanoparticles and their applications. The prepared radiosensitized nanoparticles possess a four-layer structure and a biofilm camouflage. Their multilayer structure protects the core while functionalized molecules are attached to the outer shell. The hollow structure increases drug loading capacity, and the surface-modified amino (-NH2) functional groups enhance the biocompatibility and targeting of the nanoparticles. The surface-modified biofilm facilitates evasion of the immune system and increases targeted aggregation and retention time. Furthermore, LNS-RS generates nitrite peroxide (ONOO). - LNS-RS enhances the DNA-damaging effect of radiotherapy, further improving treatment efficiency; by regulating the phenotype of TANs, LNS-RS enhances the sensitivity of tumors to radiotherapy and stimulates the immune system to attack tumors; after being disguised by a bacterial biomimetic membrane, LNS-RS exhibits intestinal retention ability in rectal cancer; LNS-RS can precisely control the release of OONO- and synchronize with the phenotype regulation of TANs to enhance the treatment of metastatic colorectal cancer and effectively inhibit liver metastasis of colorectal cancer.

[0006] To achieve the above objectives, this invention proposes a method for preparing X-ray activatable nanoparticles. The nanoparticles comprise a four-layer structure, namely: a core of NaYbF4:2%Er, a shell of NaYbF4, an outer shell of NaLuF4:15%Tb,5%Gd, and an outermost shell of NaLuF4:20%Gd.

[0007] The shell NaYbF4 is grown on the surface of the core NaYbF4:2%Er.

[0008] The outer shell, NaLuF4:15%Tb,5%Gd, is grown on the surface of the shell layer NaYbF4.

[0009] The outermost shell, NaLuF4:20%Gdshen, is grown on the surface of the aforementioned outer shell, NaLuF4:15%Tb,5%Gd.

[0010] The nanoparticles also include an amino-modified hollow silicon shell, and the above four-layer material is loaded in the core of the amino-modified hollow silicon shell.

[0011] The nanoparticles also include the photosensitive NO precursor Roussin black salt and the TGF-β inhibitor, wherein the RBS and SB525334 are loaded in the hollow cavity of amino-modified hollow mesoporous silica.

[0012] The nanoparticles also include a bacterial biofilm, which is wrapped around the surface of hollow mesoporous silica.

[0013] Furthermore, the drug loading of RBS and SB525334 in the hollow silicon shell is 6.3 wt% and 3.5 wt%, respectively.

[0014] Furthermore, the preparation method employs a seed crystal growth method.

[0015] Furthermore, the preparation method includes the following steps: S1: Er was prepared by thermal pyrolysis method 3+ Ion-doped NaYbF4 core was prepared to obtain a core of NaYbF4:2%Er.

[0016] S2: Three shells, including a NaYF4 shell, a NaLuF4:15%Tb,5%Gd outer shell, and a NaLuF4:20%Gd outer shell, are sequentially grown on the surface of the core NaYbF4:2%Er by thermal injection, to obtain the radiosensitized nanoparticle needle precursor LN.

[0017] S3: Loading LN into amino-modified hollow mesoporous silica to form LN@hmSiO-NH22.

[0018] S4: Lusen black salt and transforming growth factor-β inhibitor were encapsulated into LNS to prepare the radiosensitized nanoparticles LNS-RS.

[0019] S5: The biofilm of Staphylococcus aureus is isolated and encapsulated with LNS-RS through a polycarbonate porous membrane using an extruder to form LNSM-RS.

[0020] Furthermore, S1 specifically includes: Collect the pale yellow organic phase from a mixture of YbCl3·6H2O, ErCl3·6H2O, sodium oleate, deionized water, ethanol, and hexane.

[0021] The collected pale yellow organic isocyanate sodium oleate, LOA, OM and ODE were stirred and heated to 100°C and magnetically stirred for 60 minutes.

[0022] Ammonium fluoride was then added and kept at 100°C for 30 minutes before being cooled to room temperature to stop the reaction.

[0023] Then, after precipitation with ethanol and washing with n-hexane, the core NaYbF4:2%Er was obtained.

[0024] Furthermore, S2 specifically includes: S2.1: Using the hot injection method, NaYbF4 is coated with a NaYbF4:2%Er shell.

[0025] S2.2: The outermost NaYF4 shell is coated with NaLuF4:15%Tb,5%Gd by hot injection.

[0026] S2.3: The outermost shell of NaLuF4:15%Tb,5%Gd is coated with NaLuF4:20%Gd by hot injection.

[0027] Furthermore, S3 specifically includes: Igepal CO-520 was dispersed in cyclohexane and stirred gently at room temperature. The prepared LN was then added to the mixture and stirred. Tetraethyl orthosilicate was then added dropwise. The mixture was sealed and stirred vigorously. The precipitate collected by centrifugation with excess cyclohexane was redispersed in ethanol, and the precipitate was collected by centrifugation again. The resulting LND was dispersed in deionized water for further use.

[0028] CTAC and triethanolamine were mixed with water and completely dissolved at 80°C. Then, TEOS and bis(triethoxysilylpropyl) disulfide were added dropwise and reacted at 80°C. The collected product was then dispersed in a 1 wt% sodium chloride solution and stirred vigorously. After repeating the etching process three times, LNM was obtained.

[0029] Polyvinylpyrrolidone was added to deionized water, and then the prepared LNM was added to deionized water. The mixture was stirred at room temperature, then heated to 95°C and impregnated for 3 hours. The prepared LNH was redispersed in adiabatic ethanol, and then APTES was added. The reactants were then centrifuged and washed with ethanol to obtain the product LNS.

[0030] Furthermore, S4 specifically includes: The LNS prepared in S3 was mixed with an aqueous solution of RBS and SB525334, and the RBS and SB525334 were encapsulated in the LNS. After stirring in the dark for 24 hours, the product LNS-RS was collected by centrifugation.

[0031] Furthermore, S5 specifically includes: The biofilm of Staphylococcus aureus was separated using lysozyme and biofilm extraction buffer, mixed with LNS-RS dispersed by ultrasound, and extruded through a polycarbonate porous membrane using an extruder to form LNSM-RS.

[0032] X-rays can activate nanoparticles for use in radiotherapy of colorectal cancer.

[0033] The X-ray activated nanoparticle preparation method and its application proposed in this invention can bring the following beneficial effects: 1. The radiosensitized nanoparticles prepared by the method of this invention possess a four-layer structure and a biofilm camouflage. Their multilayer structure protects the core while functionalized molecules are attached to the outer shell. The hollow structure increases drug loading capacity, and the surface-modified amino (-NH2) functional groups enhance the biocompatibility and targeting of the nanoparticles. The surface-modified biofilm helps evade detection by the immune system and increases targeted aggregation and retention time. Furthermore, LNS-RS generates nitrite peroxide (ONOO). - LNS-RS enhances the DNA-damaging effect of radiotherapy, further improving treatment efficiency; by regulating the phenotype of TANs, LNS-RS enhances the sensitivity of tumors to radiotherapy and stimulates the immune system to attack tumors; after being disguised by a bacterial biomimetic membrane, LNS-RS exhibits intestinal retention ability in rectal cancer; LNS-RS can precisely control the release of OONO- and synchronize with the phenotype regulation of TANs to enhance the treatment of metastatic colorectal cancer and effectively inhibit liver metastasis of colorectal cancer. Attached Figure Description

[0034] The accompanying drawings, which are included to provide a further understanding of the invention and form part of this invention, illustrate exemplary embodiments of the invention and are used to explain the invention, but do not constitute an undue limitation of the invention. In the drawings: Figure 1This is a schematic diagram of the mechanism by which X-ray irradiation induces the generation of ONOO- in LNS-RS, as proposed in this invention. Figure 2 Representative transmission electron microscope (TEM) images of each layer of the structure; Figure 2 a is an electron micrograph of NaYbF4:2%Er(core) nanoparticles; Figure 2 b is an electron micrograph of NaYbF4:Er@NaYbF4(C@S1) nanoparticles; Figure 2 c is an electron micrograph of NaYbF4:Er@NaYbF@NaLuF44:15%Tb,5%Gd(C@S1@S2) nanoparticles. Figure 2 The nanoparticles d, namely NaYbF4:Er@NaYbF444 @NaLuF:15%Tb,5%Gd@NaLuF4:20%Gd (C@S1@S2@S3), exhibit a uniform size distribution with average sizes of approximately 13 nm, 23 nm, 38 nm, and 48 nm, respectively, and a scale bar of 50 nm.

[0035] Figure 3 This is a schematic diagram of the LNS structure; Figure 3 Figure a shows a high-angle dark-field scanning transmission electron microscope (HAADF-STEM) image of LN@hmSiO2 (LNS) nanoparticles; Figure bf shows the elemental mapping. Figure 4 A schematic diagram illustrating the ability of LNS-RS to generate ONOO- under X-ray irradiation; Figure 4 a represents the radioluminescence emission spectrum of LNS under X-rays; Figure 4 b is the near-infrared emission spectrum of LNS under 980 nm excitation light in the second region; Figure 4 c represents the pathway by which the emitted light from LNS under ultraviolet / near-infrared irradiation excites RBS to generate NO; Figure 4 d represents the UV-Vis absorption spectra of four groups of samples with added NBT: PBS(-), LNS(-), PBS(+), and LNS(+). Figure 4 e represents the UV-Vis absorption spectra of samples such as LNS(-), LNS-R(-), LNS(+), and LNS-R(+); Figure 4 f represents the fluorescence spectra of LNS(-), LNS-R(-), LNS(+), and LNS-R(+); (-) indicates no X-ray irradiation; (+) indicates X-ray irradiation.

[0036] Figure 5 To verify the effects of various experimental conditions on cell viability in the CCK-8 assay; Figure 5 Viability of CT26 cells incubated with different RBS concentrations before and after X-ray irradiation of 4 Gy; Figure 5 b. Viability of CT26 cells after incubation with different concentrations of SB525334; Figure 5c. Schematic diagram of CT26 cell viability analysis under PBS (-), LNS (-), LNS-R (-), PBS (+), LNS (+), and LNS-R (+) conditions; (-) indicates no X-ray irradiation; (+) indicates X-ray irradiation treatment.

[0037] Figure 6 This diagram illustrates the intracellular generation and cytotoxicity of ONOO- in CT26 cells.

[0038] Figure 6a shows a schematic diagram of confocal laser scanning microscopy (CLSM) images of CT26 cells under different treatments, used to detect the generation of O2•-, NO, ONOO- and DNA double-strand breaks (γ-H2AX) in the cells; Figure 6b shows flow cytometry analysis of apoptosis in CT26 cells under different treatments. Figure 7 A schematic diagram illustrating the enhanced recruitment and regulation of tumor-associated neutrophils; Figure 7 a shows a schematic diagram of MPO and Ly-6G immunohistochemical (IHC) staining of tumors isolated from PBS-treated G1 group, X-ray-treated G2 group, and X-ray + LNSM-RS-treated G5 group; Figure 7 b is a heatmap illustrating the Z-value expression of N2-related TANs via RNA sequencing (RNA-Seq). Figure 7 c represents the average fluorescence intensity of CXCR2 in TANs; Figure 7 d represents the average fluorescence intensity of Fas in TANs; Figure 7 e represents the average fluorescence intensity of Icam1 in TANs; Figure 7 f is a volcano plot of differentially expressed genes (DEGs) analysis (P<0.05, fold change>2); Figure 7 g is a schematic diagram of KEGG enrichment analysis of all upregulated genes in TANs of G1 and G5 mice, where NES: normalized enrichment score; FDR: false detection rate. Color labels indicate positive correlation (red) or negative correlation (blue). Figure 7 h is a heatmap of Z-values ​​for the expression of N1-related TANs via RNA sequencing (RNA-Seq); Figure 7 i represents the volcano plot for genome enrichment analysis; Figure 8 This is a schematic diagram illustrating the in vivo antitumor effect against colorectal cancer. Figure 8a is a schematic diagram of bioluminescence imaging of the entire animal body of a mouse carrying orthotopic colorectal cancer after different treatments within 21 days. Figure 8 b represents quantification Figure 8 A schematic diagram of the growth curve of a single tumor obtained by biofluorescence in a; Figure 8 c is a representative flow cytometry image of CD3+CD8+ T cells from CD45+ cells in tumor tissue; Figure 8 d is a schematic diagram showing the number of CD3+ T cells; Figure 8 e is a schematic diagram showing the number of CD8+ T cells; Figure 8 f is a schematic diagram showing the number of CD3+ CD8+ T cells; Figure 8 g is a schematic diagram showing the number in CD45+ cells; Figure 8 h is a schematic diagram of the survival rates of mice in different groups after 60 days of treatment (G1, PBS; G2, X-ray; G3, X-ray+LNSM-R; G4, X-ray+LNSM-S; G5, X-ray+LNSM-RS); Figure 9 A schematic diagram of the average tumor growth curve in mice with orthotopic colorectal cancer; Figure 9 a is Figure 8 A schematic diagram of the bioluminescence quantification results of mice with orthotopic colorectal cancer that received various treatments in Figure a; Figure 9 b is a schematic diagram of the weight change curves of mice with orthotopic colorectal cancer that received various treatments; Figure 10 A schematic diagram illustrating the validation of liver metastasis inhibition in a mouse model of metastatic orthotopic colorectal cancer; Figure 10a is a schematic diagram of the experimental design for verifying liver metastasis inhibition; Figures 10b-d show photographs of the livers of mice with orthotopic colorectal cancer treated with PBS, X-rays, and X-rays + LNSM-RS (n=3), respectively, along with hematoxylin and eosin (H&E) staining. Figure 11 The images show the spectra of different LNS prepared in Examples 1-4 under X-ray irradiation. Detailed Implementation

[0039] To more clearly illustrate the overall concept of the present invention, a detailed description will be provided below with reference to the accompanying drawings and examples.

[0040] Example 1: An X-ray activatable nanoparticle comprises a four-layer structure: a core of NaYbF4:2%Er, a shell of NaYbF4, an outer shell of NaLuF4:15%Tb,5%Gd, and an outermost shell of NaLuF4:20%Gd. The shell NaYbF4 grows on the surface of the core NaYbF4:2%Er; The outer shell NaLuF4:15%Tb,5%Gd is grown on the surface of the shell layer NaYbF4. The outermost shell NaLuF4:20%Gdshen is grown on the surface of the above-mentioned outer shell NaLuF4:15%Tb,5%Gd. An X-ray activatable nanoparticle also includes a bacterial biofilm and an amino-modified hollow silicon shell, with all four layers housed within the core of the amino-modified hollow silicon shell.

[0041] The photosensitive NO precursor, Roussin black salt (RBS), and the TGF-β inhibitor (SB525334) are loaded in the hollow cavity of the above-mentioned amino-modified hollow mesoporous silica.

[0042] The drug loading of RBS and SB525334 in the hollow silicon shell is 6.3 wt% and 3.5 wt%, respectively.

[0043] Bacterial biofilms are wrapped around the surface of hollow mesoporous silica.

[0044] An X-ray activatable nanoparticle preparation method is disclosed, which employs a seed crystal growth method. The average material sizes of the core, the encapsulated shell, the encapsulated outer shell, and the encapsulated outermost shell of the X-ray activatable nanoparticle are 13 nm, 23 nm, 38 nm, and 48 nm, respectively.

[0045] A method for preparing X-ray activatable nanoparticles, the specific preparation method including the following steps S1: Er3+ ion-doped NaYbF4 cores were prepared by thermal decomposition to obtain core NaYbF4:2%Er; First, using a thermochemical method, 0.98 mmol of YbCl3·6H2O, 0.02 mmol of ErCl3·6H2O, and 3 mmol of sodium oleate were mixed with 3 mL of deionized water, 3.5 mL of absolute ethanol, and 7 mL of hexane. The bottom aqueous phase was discarded, and a pale yellow organic phase containing Yb and Er-OA was collected. Then, 5 mmol of sodium oleate, 5.2 mmol of LOA, 5.1 mL of OM (oleylamine), and 9 mL of ODE (octadecene) were added. The mixture was heated to 100 °C under N2 protection and vigorously stirred magnetically for 60 minutes. Subsequently, 5 mmol of ammonium fluoride was added to the solution, and the mixture was maintained at 100 °C for another 30 minutes. Then, the reaction mixture was heated to 300 °C and maintained for 30 minutes. Finally, the temperature was lowered to room temperature to stop the reaction. After precipitation with ethanol and washing with n-hexane, NaYbF4:2%Er core nanoparticles were obtained.

[0046] S2: Three shells, including a NaYbF4 shell, a NaLuF4:15%Tb,5%Gd outer shell, and a NaLuF4:20%Gd outermost shell, are sequentially grown on the surface of the core NaYbF4:2%Er using a thermal injection method to obtain the radiosensitized nanoparticle needle precursor NaYbF:Er@NaYbF4@NaLuF:15%Tb,5%Gd@NaLuF4:20%Gd, i.e., LN; specifically, the following steps are included: S2.1: Using the hot injection method, NaYbF4 is coated with a NaYbF4:2%Er shell; First, 2.5 mL (0.25 mmol) of NaYbF4:2%Er core nanoparticles (dispersed in hexane) was mixed with 6 mL of OA (oleic acid) and 15 mL of ODE (octadecene) in a three-necked flask (250 mL). The mixture was heated to 120 °C and held for 30 minutes, then heated to 300 °C under N2 protection. Next, equal amounts (1 mL) of the shell precursor containing 0.2 mmol of Yb-OA and 0.2 mmol of Na-OA were continuously injected into the solution every 10 minutes. After seven injections of the shell precursor, the reaction was allowed to cool to room temperature. The NaYbF4:2%Er@NaYbF4 nanoparticles were collected in 10 mL of n-hexane after precipitation with ethanol and washing with n-hexane.

[0047] S2.2: The outermost NaYF4 shell is coated with NaLuF4:15%Tb,5%Gd by hot injection. 3 mL (0.25 mmol) of NaYbF4:2%Er@NaYbF4 nanoparticles (dispersed in hexane) was mixed with 6 mL of OA (oleic acid) and 15 mL of ODE (octadecene) in a three-necked flask (250 mL). The mixture was heated to 120 °C and maintained for 30 min, then heated to 300 °C under N2 protection. Then, every 10 min, equal volumes (1 mL) of a shell precursor containing 0.2 mmol of Lu:15%Tb,2%Gd-OA and 0.2 mmol of Na-OA were continuously injected into the solution. After seven injections of the shell precursor, the reaction was allowed to cool to room temperature. After precipitation with ethanol and washing with n-hexane, the NaYbF4:2%Er@NaYbF4@NaLuF4:15%Tb,5%Gd nanoparticles were collected in 10 mL of n-hexane.

[0048] S2.3: The outermost NaLuF4:15%Tb,5%Gd shell is coated with NaLuF4:20%Gd by hot injection method; 3 mL (0.25 mmol) of NaYbF4:2%Er@NaYbF4@NaLuF4:15%Tb,5%Gd nanoparticles (dispersed in hexane) was mixed with 6 mL of OA and 15 mL of ODE in a three-necked flask (250 mL). The mixture was heated to 120 °C and maintained for 30 min, then heated to 300 °C under N2 protection. Then, every 10 min, an equal volume (1 mL) of the shell precursor containing 0.2 mmol of Lu:20%Gd-OA and 0.2 mmol of Na-OA was continuously injected into the solution. After 7 injections of the shell precursor, the reaction was allowed to cool to room temperature. After precipitation with ethanol and washing with n-hexane, the NaYbF4:2%Er@NaYbF4@NaLuF4:15%Tb,5%Gd@NaLuF4:20%Gd (LN) nanoparticles were collected in 10 mL of n-hexane.

[0049] S3: LN is loaded into amino-modified hollow mesoporous silica to form LN@hmSiO-NH22 (LNS). The hollow mesoporous silica is prepared by selective etching. 1 mL of Igepal CO-520 was dispersed in 20 mL of cyclohexane and gently stirred at room temperature for 40 minutes. The prepared LN (dissolved in hexane, 2 mL) was then added to the mixture and stirred for 3 hours. Next, 200 μL of tetraethyl orthosilicate (TEOS) was added dropwise, the mixture was sealed, and stirred vigorously for 48 hours. The precipitate collected by centrifugation with excess cyclohexane was redispersed in ethanol and collected by centrifugation (washing at least three times). The resulting LND was dispersed in 10 mL of deionized water for further use. 2 g of CTAC and 20 mg of triethanolamine were mixed with 20 mL of water and completely dissolved at 80 °C for 30 minutes. Then, 200 μL of TEOS and 100 μL of bis(triethoxysilylpropyl) disulfide were added dropwise, and the mixture was reacted at 80 °C for 1 hour. The collected product was then dispersed in a 1 wt% sodium chloride solution (methanol) and stirred vigorously for 24 hours to remove the CTAC template. After repeating the etching procedure three times, LNM was obtained. Weigh 250 mg of polyvinylpyrrolidone (PVP) and add it to 10 mL of deionized water. Then add the prepared LNM to 5 mL of deionized water and stir at room temperature for 30 minutes. Next, heat the mixture to 95°C and impregnate for 3 hours. To impart -NH2 functional groups to the HMSN surface, first redisperse the prepared LNH in 20 mL of adiabatic ethanol, then add 200 μL of APTES. The reaction mixture is then centrifuged and washed with ethanol at least three times to remove residual APTES. The resulting product (LNS) is dispersible in water.

[0050] S4: The radiosensitized nanoparticles LNS-RS were prepared by encapsulating Rusen black salt (RBS) and transforming growth factor-β (TGF-β) inhibitor (SB525334) into LNS; Mix 1 mg of LNS with 2 mL of 0.2 mM RBS aqueous solution or 10 mL of 0.02 M LSB525334 or 2 mL of 0.2 mM RBS aqueous solution and 10 mL of 0.02 M LSB525334, and encapsulate the RBS and LSB525334 into the LNS. After stirring in the dark for 24 hours, collect the products (LNS-R, LNS-S, and LNS-RS) by centrifugation, wash three times with water, and finally store in PBS solution for later use.

[0051] S5: Bacterial biomimetic membrane camouflage; The biofilm of Staphylococcus aureus was separated using lysozyme and biofilm extraction buffer, and then mixed with LNS-RS dispersed by ultrasound. The mixture was then extruded through 800, 400 and 200 nm polycarbonate porous membranes for five cycles using an Avanti mini extruder to form LNSM-RS.

[0052] Test 1: (1) Electron microscopic images of the core and encapsulated shell of LNS; LN was prepared using a seed crystal growth method. Figure 2 Representative transmission electron microscopy images of each layer of the structure are shown. NaYbF4:2%Er(core, Figure 2 a) Nanoparticles, NaYbF4: Er@NaYbF4(C@S1, Figure 2 b) Nanoparticles, NaYbF4:Er@NaYbF@NaLuF44:15%Tb,5%Gd(C@S1@S2, Figure 2 c) Nanoparticles, NaYbF:Er@NaYbF444@NaLuF:15%Tb,5%Gd@NaLuF4:20%Gd(C@S1@S2@S3, Figure 2 d) The nanoparticles exhibit a uniform size distribution with average sizes of approximately 13 nm, 23 nm, 38 nm and 48 nm, respectively, and a scale bar of 50 nm.

[0053] (2) Transmission electron microscopy images of LNS and mapping of each element; like Figure 3 As shown, high-angle dark-field scanning transmission electron microscopy (HAADF-STEM) images (a) and elemental mapping (bf) of LN@hmSiO2 (LNS) nanoparticles. Test 2: LNS-RS ONOO- generation capability; To evaluate the ONOO- generation capacity of LNS-RS, its ability to generate 2•- and NO must first be examined. Based on chemical properties, the reduction in the absorption band at 260 nm is due to O2•- inducing NBT degradation. Under X-ray irradiation, the absorbance of NBT in the PBS group decreased slightly, due to photoinduced effects and Compton scattering. Thanks to the excellent X-ray attenuation coefficients of the lanthanide elements (Lu, Gd, Tb, Yb, Er) used in this invention, the NBT degradation rate of the LNS group (23.5%) was significantly higher than that of the PBS group (degradation rate 8.0%), indicating efficient O2•- generation under X-ray irradiation. Figure 4 d). Furthermore, the radiative emission of LNS in the ultraviolet / visible (UV / Vis) range, including the 310 nm emission from Gd³⁺ ions and the 490, 546, 586, and 625 nm emission from Tb³⁺ ions, closely matches the absorption spectrum of RBS molecules, ensuring high energy transfer (ET) efficiency of X-ray induced photons to RBS molecules, thereby generating NO( Figure 4 c). Compared to unirradiated LNS-R, X-ray irradiated LNS-R showed a decrease in absorption intensity and exhibited scintillation absorption at 540 nm, which confirmed the degradation of RBS and the successful formation of NO, respectively. Figure 4 e). Similarly, the released NO was quantitatively detected using Griess analysis under different doses of X-ray irradiation. Figure 4 As shown in f, in LNS-R, a significant emission spectrum only appears at 406 nm after X-ray irradiation, indicating that ONOO- was successfully generated under X-ray triggering.

[0054] Test 3: (1) CCK-8; X-ray-induced cytotoxicity of LNS-RS was further evaluated using a CCK-8 assay. First, cell viability was assessed by culturing CT26 cells for 24 hours with RBS and SB525334 alone. Figure 5 As shown in Figure a, the cell viability of CT26 cells treated with RBS (40 μM or less) was comparable to that of cells cultured with PBS, even after exposure to 4 Gy X-rays, indicating that RBS induced only negligible cytotoxicity. It is noteworthy that the maximum dose of SB525334 used in the experiment was 20 μM, because at concentrations below 40 μM, SB525334 had little effect on cell viability. Figure 5 b) Figure 5c shows the effect of LNS-RS on CT26 cell viability. Compared with unirradiated CT26 cells, cell viability decreased in all X-ray irradiation groups. Among them, LNS-RS(+) showed significant ONOO- generation capacity, exhibited the most significant inhibitory effect on cell proliferation, and had the lowest cell survival rate (<40%).

[0055] (2) Detection of DNA damage in CT26 cells; Subsequently, DNA damage in CT26 cells was detected by measuring the expression level of phosphohistone H2AX (γ-H2AX). Red immunofluorescence was observed in all X-ray-treated cells, with the LNS-RS(+) group showing the most severe DNA damage, likely due to the strong DNA-disrupting ability of the generated ONOO-. Figure 6 a). Furthermore, Annexin V-FITC / propidium iodide (PI) staining for apoptosis also showed that cells treated with LNS-RS after X-ray irradiation exhibited the most severe apoptosis. Figure 6 (b) In summary, all these results confirm that our designed RBS-loaded LNS can effectively generate ONOO- under X-ray irradiation, thereby exerting a strong cytotoxic effect on tumor cells.

[0056] (3) Enhanced recruitment and regulation of tumor-associated neutrophils; To elucidate the underlying mechanisms by which neutrophils exert significant antitumor therapeutic effects and potently activate antitumor immune responses, we investigated the regulation of tumor-associated neutrophils (TANs). First, we performed IHC staining on neutrophil biomarkers Ly6G and myeloperoxidase (MPO) to investigate the presence of neutrophils at tumor sites. Figure 7 a). The results showed that neutrophils were rarely detected in the G1 group, slightly increased in the G2 and G4 groups, and more in the G3 and G5 groups. These results indicate that massive infiltration of TANs is significantly enhanced in the strong inflammatory response induced by ONOO- production. To further understand the neutrophil phenotype, we first analyzed the expression of neutrophil markers using flow cytometry. The results showed that the signal of the N2 phenotype marker CXCR2 was significantly decreased in the G5 group compared with the G1 and G2 groups (a). Figure 7 c). Conversely, Fas (a phenotype associated with neutrophil N1) was observed in group G5. Figure 7 d) and Icam1 ( Figure 7e) Increased expression. This observation suggests that X-ray-irradiated LNSM-RS may have the potential to promote tumor-associated neutrophil (TAN) polarization towards the N1 phenotype. Similar expression of N1- and N2-related genes was found between the G2 and G1 groups. However, in the G5 group, N2-related genes were significantly downregulated ( Figure 7 b), N1-related genes are upregulated ( Figure 7 Based on these findings, it can be concluded that most TANs recruited in the tumor microenvironment initially exhibit an N2 phenotype, and X-ray treatment alone has no significant effect on their phenotype. However, the addition of LNSM-RS effectively reprogrammed TANs from a tumor-supporting N2 phenotype to an anti-tumor N1 phenotype. Furthermore, comparing the G5 group with the G1 group ( Figure 7 i) Comparison of the sorted neutrophils also revealed significantly enhanced expression characteristics of chemokine signaling pathways, T cell receptor signaling pathways, and apoptosis. In summary, neutrophils recruited from orthotopic colorectal cancer were effectively reprogrammed from the N2 phenotype to the N1 phenotype via X-ray + LNSM-RS treatment. This reprogramming involving gene expression regulation leads to the upregulation of immune regulatory signaling pathways, the release of immune regulatory factors, the activation of CD3+CD8+ T cells, and ultimately, effective anti-tumor immunity.

[0057] Test 4: (1) In vivo antitumor activity in a mouse model of colorectal cancer; 2x10 6 Luc-CT26 cell suspension was injected into the cecal wall of a 50 μL PBS solution containing 10 μg / μL matrigel. The cecum was then gently returned to the abdominal cavity and sutured. Thirteen days after Luc-CT26 cell inoculation, mice were used for in vivo antitumor experiments and randomly divided into five groups (n=5). The mice received PBS (G1), X-rays (G2), X-rays + LNSM-R (G3), X-rays + LNSM-S (G4), and X-rays + LNSM-RS (G5), respectively. Twenty-four hours after intragastric administration, all mice except those in group G1 received X-ray irradiation at a dose of 4 Gy. For the next 22 days, mouse body weight was recorded every two days, and tumor burden was monitored weekly using bioluminescence imaging. Furthermore, mouse survival was monitored for 60 days.

[0058] Mice administered PBS by gavage (G1) experienced uncontrolled growth, with a 21-day mortality rate of 30%. X-ray treatment in the G2 group showed only a slight effect on tumor growth, with a 21-day mortality rate of 20%. Mice treated with X-ray + LNSM-R (G3) or X-ray + LNSM-S (G4) showed continued tumor growth, but at a significantly slower rate compared to the G1 and G2 groups. Notably, only the X-ray + LNSM-RS (G5) group showed a decreasing trend in tumor bioluminescence signal, and the mice maintained stable body weight, indicating a substantial role in tumor regression. Figure 8 a,b) In addition, to verify the effective activation of immune regulation, flow cytometry analysis was performed on T cells isolated from orthotopic colorectal cancer after various treatments. Figure 8 (cg). Treatment with X-rays and LNSM-RS significantly increased the number of CD3+ T cells and CD8+ T cells. Specifically, compared to the G2 group treated with X-rays, the percentage of CD3+ T cells increased from 9.93% to 31.60%, and the percentage of CD8+ T cells increased from 11.94% to 24.88%. Furthermore, the expression level of CD3+CD8+ T cells in CD45+ T cells also increased significantly by approximately 14.35%, providing clear evidence of successful T cell activation.

[0059] Furthermore, the long-term survival rate of mice reached 80% within 60 days, which further confirms that X-ray activated LNSM-RS has a high therapeutic effect on orthotopic colorectal cancer. Figure 8 h, Figure 9 b).

[0060] (2) Evaluation of the anti-metastatic effect of a mouse model of metastatic colorectal cancer; Given that liver metastases in colorectal cancer patients significantly impact clinical survival, we further evaluated antitumor immunity in a metastatic orthotopic mouse model of colorectal cancer. Figure 10 a). Balb / c mice carrying orthotopic colorectal cancer were randomly divided into three groups. After 21 days of treatment with PBS, X-ray, and X-ray + LNSM-RS, respectively, the tumor metastasis in the liver of each group of mice was characterized by hematoxylin-eosin (H&E) staining. Figure 10 Metastatic tumors were clearly found in the livers of mice treated with PBS. Even in the radiotherapy group, small tumors were present in the liver. In contrast, mice treated with a combination of LNSM-RS and X-rays showed no metastatic tumors. These results clearly demonstrate that LNSM-RS combined with X-ray therapy has an effective anti-metastatic effect.

[0061] Example 2: The difference between this embodiment and Embodiment 1 is that: The outermost shell of the nanoparticles in Example 1 was replaced with NaLuF4:15%Tb,5%Gd.

[0062] Step S2.3 in Example 1 is changed to: using a hot injection method to coat the outermost NaLuF4:15%Tb,5%Gd shell with NaLuF4:2%Ce. 3 mL (0.25 mmol) of NaYbF4:2%Er@NaYbF4@NaLuF4:15%Tb,5%Gd nanoparticles (dispersed in hexane) was mixed with 6 mL of LOA and 15 mL of ODE in a three-necked flask (250 mL). The mixture was heated to 120 °C and maintained for 30 min, then heated to 300 °C under N2 protection. Then, every 10 min, equal amounts (1 mL) of the shell precursor containing 0.2 mmol Lu:2%Ce-OA and 0.2 mmol Na-OA were continuously injected into the solution. After 7 injections of the shell precursor, the reaction was allowed to cool to room temperature. After precipitation with ethanol and washing with n-hexane, the NaYbF4:2%Er@NaYbF4@NaLuF4:15%Tb,5%Gd@NaLuF4:2%Ce nanoparticles were collected in 10 mL of n-hexane.

[0063] Example 3: The difference between this embodiment and Embodiment 1 is that: The outermost shell of the nanoparticles in Example 1 was replaced with NaLuF4:18%Gd,2%Ce.

[0064] Step S2.3 in Example 1 is changed to: using a hot injection method to coat the outermost NaLuF4:15%Tb,5%Gd shell with NaLuF4:18%Gd,2%Ce. 3 mL (0.25 mmol) of NaYbF4:2%Er@NaYbF4@NaLuF4:15%Tb,5%Gd nanoparticles (dispersed in hexane) was mixed with 6 mL of OA and 15 mL of ODE in a three-necked flask (250 mL). The mixture was heated to 120 °C and held for 30 min, then heated to 300 °C under N2 protection. Then, every 10 min, equal volumes (1 mL) of the shell precursor containing 0.2 mmol Lu:18%Gd, 2%Ce-OA, and 0.2 mmol Na-OA were continuously injected into the solution. After 7 injections of the shell precursor, the reaction was allowed to cool to room temperature. After precipitation with ethanol and washing with n-hexane, the NaYbF4:2%Er@NaYbF4@NaLuF4:15%Tb,5%Gd@NaLuF4:18%Gd,2%Ce nanoparticles were collected in 10 mL of n-hexane.

[0065] Example 4: The difference between this embodiment and Embodiment 1 is that: The outermost shell of the nanoparticles in Example 1 was replaced with NaLuF4:18%Gd,10%Ce.

[0066] The step S2.3 in Example 1 is changed to: using a hot injection method to coat the outermost NaLuF4:15%Tb,5%Gd shell with NaLuF4:18%Gd,10%Ce. 3 mL (0.25 mmol) of NaYbF4:2%Er@NaYbF4@NaLuF4:15%Tb,5%Gd nanoparticles (dispersed in hexane) was mixed with 6 mL of OA and 15 mL of LODE in a three-necked flask (250 mL). The mixture was heated to 120 °C and maintained for 30 min, then heated to 300 °C under N2 protection. Then, every 10 min, equal amounts (1 mL) of the shell precursor containing 0.2 mmol Lu:18%Gd, 10%Ce-OA, and 0.2 mmol Na-OA were continuously injected into the solution. After 7 injections of the shell precursor, the reaction was allowed to cool to room temperature. After precipitation with ethanol and washing with n-hexane, the NaYbF4:2%Er@NaYbF4@NaLuF4:15%Tb,5%Gd@NaLuF4:18%Gd,10%Ce nanoparticles were collected in 10 mL of n-hexane.

[0067] The differences in optical properties of the LNS prepared in Examples 1-4 were studied under X-ray irradiation.

[0068] Under X-ray irradiation at 50 kV, the characteristic emission peaks of Gd3+ and Tb3+ ions were successfully obtained, with 310 nm corresponding to the P of gadolinium ions. 3+6 7 / 2 →S 6 7 / 2 The transitions, 490, 546, 586, and 625 nm, correspond to terbium. 3+ D 5 4→F 7 J (J=3, 4, 5 and 6) transformation.

[0069] according to Figure 11 It can be observed that the LNS in Examples 1-4 exhibits characteristic emission peaks at 310, 490, 546, 586 and 625 nm under X-ray irradiation. Therefore, it can be determined that the LNSM-RS prepared based on LNS nanoparticles in Examples 1-4 are all applicable.

[0070] In summary, this invention proposes a rationally designed X-ray activated nanosystem (LNSM-RS) aimed at improving the effectiveness of low-dose radiation radiotherapy for colorectal cancer. This system has been proven to control the in-situ generation of ONOO through radioluminescence. - Enhanced radiosensitization and simultaneous reversal of tumor-promoting tumor melanoma (TME) through phenotypic polarization of TANs. Results indicate that the TME reversal-modified ONOO method employed in this invention... - Sensitized radiotherapy has proven highly effective in treating metastatic colorectal cancer, significantly inhibiting the growth of orthotopic colorectal cancer, suppressing liver metastasis, and preventing tumor recurrence. The strategy employed in this invention—reprogramming neutrophils to reverse the tumor microenvironment—provides strong evidence for improving radiotherapy efficacy. This may offer a promising strategy for enhancing radiotherapy outcomes, not limited to colorectal cancer; its applicability in other tumor models warrants further exploration.

[0071] The present invention relates to X-ray-activated nanoparticles for use in radiotherapy of colorectal cancer.

[0072] The various embodiments in this specification are described in a progressive manner. Similar or identical parts between embodiments can be referred to interchangeably. Each embodiment focuses on describing the differences from other embodiments. In particular, the system embodiments are basically similar to the method embodiments, so the description is relatively simple; relevant parts can be referred to the descriptions in the method embodiments.

[0073] The above description is merely an embodiment of the present invention and is not intended to limit the invention. Various modifications and variations can be made to the present invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principle of the present invention should be included within the scope of the claims of the present invention.

Claims

1. A method for preparing X-ray-activated nanoparticles, characterized in that, The nanoparticles comprise a four-layer structure, which consists of: a core NaYbF4:2%Er, a shell NaYbF4, an outer shell NaLuF4:15%Tb,5%Gd, and an outermost shell NaLuF4:20%Gd. The shell NaYbF4 grows on the surface of the core NaYbF4:2%Er; The outer shell NaLuF4:15%Tb,5%Gd is grown on the surface of the shell layer NaYbF4. The outermost shell NaLuF4:20%Gd is grown on the surface of the above-mentioned outer shell NaLuF4:15%Tb,5%Gd; The nanoparticles also include an amino-modified hollow silicon shell, and the above four-layer material is loaded in the core of the amino-modified hollow silicon shell. The nanoparticles also include the photosensitive NO precursor Roussin black salt and SB525334. Roussin black salt and SB525334 are loaded in the hollow cavity of amino-modified hollow mesoporous silica. The nanoparticles also include a bacterial biofilm, which is wrapped around the surface of hollow mesoporous silica. The preparation method includes the following steps: S1: Er was prepared by thermal pyrolysis method 3+ Ion-doped NaYbF4 core, yielding a core of NaYbF4:2%Er; S2: Three shells, including a NaYF4 shell, a NaLuF4:15%Tb,5%Gd outer shell, and a NaLuF4:20%Gd outer shell, are sequentially connected and grown on the surface of the core NaYbF4:2%Er by a hot injection method to obtain the radiosensitized nanoparticle needle precursor LN. S3: Loading LN into amino-modified hollow mesoporous silica to form LNS; S4: Roussin black salt and SB525334 were encapsulated into LNS to prepare the radiosensitized nanoparticles LNS-RS; S5: The biofilm of Staphylococcus aureus is isolated and encapsulated with LNS-RS through a polycarbonate porous membrane using an extruder to form LNSM-RS.

2. The method for preparing X-ray-activated nanoparticles according to claim 1, characterized in that, The loading amounts of Roussin black salt and SB525334 in the hollow silicon shell are 6.3 wt% and 3.5 wt%, respectively.

3. The method for preparing X-ray-activated nanoparticles according to any one of claims 2, characterized in that, S1 specifically includes: Collect the pale yellow organic phase from a mixture of YbCl3·6H2O, ErCl3·6H2O, sodium oleate, deionized water, ethanol, and hexane; The collected pale yellow organic isooleate sodium oleate, LOA, OM and ODE were stirred, heated to 100°C and magnetically stirred for 60 minutes. Ammonium fluoride was then added and the mixture was kept at 100°C for 30 minutes before being cooled to room temperature to stop the reaction. Then, after precipitation with ethanol and washing with n-hexane, the core NaYbF4:2%Er was obtained.

4. The method for preparing X-ray-activated nanoparticles according to claim 3, characterized in that, S2 specifically includes: S2.1: Using the hot injection method, NaYbF4 is coated with a NaYbF4:2%Er shell; S2.2: NaLuF4:15%Tb,5%Gd is coated with a NaYF4 shell by hot injection method; S2.3: The outer shell of NaLuF4:15%Tb,5%Gd is coated with NaLuF4:20%Gd by hot injection.

5. The method for preparing X-ray-activated nanoparticles according to claim 4, characterized in that, S3 specifically includes: IgepalCO-520 was dispersed in cyclohexane and stirred gently at room temperature. The prepared LN was added to the mixture and stirred. Then, tetraethyl orthosilicate was added dropwise. The mixture was sealed and stirred vigorously. The precipitate collected by centrifugation with excess cyclohexane was redispersed in ethanol and collected by centrifugation again. The resulting LND was dispersed in deionized water for further use. CTAC and triethanolamine were mixed with water and completely dissolved at 80°C. Then, TEOS and bis-[3-(triethoxysilyl)propyl]-disulfide were added dropwise. After reacting at 80°C, the collected product was dispersed in a methanol solution containing 1 wt% sodium chloride and stirred vigorously. The above operation was repeated three times to obtain LNM. Polyvinylpyrrolidone was added to deionized water, and the prepared LNM was added. The mixture was stirred at room temperature, and then heated to 95°C and impregnated for 3 hours to obtain LNH. The prepared LNH was then redispersed in adiabatic ethanol, and after adding APTES, the reactants were collected by centrifugation and washed with ethanol to obtain the product LNS.

6. The method for preparing X-ray-activated nanoparticles according to claim 5, wherein step S4 specifically includes: The LNS obtained from S3 was mixed with Roussin black salt aqueous solution and SB525334 aqueous solution. Roussin black salt and SB525334 were encapsulated in LNS. After stirring in the dark for 24 hours, the product LNS-RS was collected by centrifugation.

7. The method for preparing X-ray-activated nanoparticles according to claim 6, characterized in that, S5 specifically includes: The biofilm of Staphylococcus aureus was separated using lysozyme and biofilm extraction buffer, mixed with LNS-RS dispersed by ultrasound, and extruded through a polycarbonate porous membrane using an extruder to form LNSM-RS.

8. An X-ray activatable nanoparticle, characterized in that, It is prepared by the preparation method described in any one of claims 1-7.

9. The application of the X-ray activatable nanoparticles as described in claim 8 in the preparation of radiotherapy drugs for colorectal cancer.